Abstract Lidocaine (lignocaine) was given in 42 episodes of status epilepticus (SE) in 36 patients either because of limited pulmonary reserve (22 patients) or because of lack of response to diazepam (14 patients). Lidocaine (1-5-2 mg/lkg) was given intravenously in two minutes. A further identical bolus was infused if no response had occurred or if seizures recurred. With the first bolus 11 episodes of SE did not stop, but 31 responded, always in less than one minute. In 19 episodes, however, this response lasted less than 30 minutes. Twelve episodes did not recur, but 30 needed a second bolus because of recurrence. Of these, 19 episodes responded at once but SE reappeared in seven. In these seven episodes the mean control time with the second dose was 102 minutes. Five of these subsequently responded to a continuous infusion of lidocaine. Eleven patients, who had not responded to the first bolus, had no response to the second. Lidocaine is a drug that may be epileptogenic at high doses. At the doses used here, however, lidocaine seems to be a rapid acting anticonvulsant, useful in the short term management of SE and may be indicated in patients in whom respiratory or consciousness depression is undesirable and in those with no response to diazepam. The absence of response to lidocaine indicates SE resistant to treatment and poor prognosis. These data show that prompt lidocaine administration may be worthwhile when management of respiratory depression is not possible.
because of lack of response to diazepam (14 patients). Lidocaine (1-5-2 mg/lkg) was given intravenously in two minutes. A further identical bolus was infused if no response had occurred or if seizures recurred. With the first bolus 11 episodes of SE did not stop, but 31 responded, always in less than one minute. In 19 episodes, however, this response lasted less than 30 minutes. Twelve episodes did not recur, but 30 needed a second bolus because of recurrence. Of these, 19 episodes responded at once but SE reappeared in seven. In these seven episodes the mean control time with the second dose was 102 minutes. Five of these subsequently responded to a continuous infusion of lidocaine. Eleven patients, who had not responded to the first bolus, had no response to the second. Lidocaine is a drug that may be epileptogenic at high doses. At the doses used here, however, lidocaine seems to be a rapid acting anticonvulsant, useful in the short term management of SE and may be indicated in patients in whom respiratory or consciousness depression is undesirable and in those with no response to diazepam. The absence of response to lidocaine indicates SE resistant to treatment and poor prognosis. These data show that prompt lidocaine administration may be worthwhile when management of respiratory depression is not possible. This may finally avoid the necessity of anaesthesia or delay it allowing us time, for instance, to transfer the patients to an intensive care unit. Neither the ideal dosage nor the temporal profile of this drug have been stated in previous studies. With the initial dose used (about 1-5-2 mg/kg body weight) 74% of episodes of SE were controlled. Although prompt, this response was habitually short; 19 episodes recurred, in 18 the response being shorter than 30 minutes. The prolonged response to this first bolus of lidocaine observed in the remaining 12 episodes is probably better explained by the phenytoin. Though we did not study the pharmacokinetics of lidocaine in our patients it is well known that after an iv bolus lidocaine is initially distributed to a few highly perfused tissues (heart, brain, kidneys, liver).'6 This allows for the rapid achievement of therapeutic lidocaine concentrations by a dose smaller than that necessary to produce comparable concentrations after complete distribution. Early plasma concentrations, however, decrease rapidly because of the redistribution to peripheral tissues. Therefore, the half life of this initial bolus is in the range of four to eight minutes,"6 thus explaining the results with the first bolus.
In contrast with the usual brief action seen with the first dose, 19 episodes had a more prolonged response to the second dose. Although this long response could be explained by the action of the phenytoin, our data do not support that. The response to this second bolus was again immediate ( < one minute), and in the 18 episodes with short initial response to the first bolus, lidocaine alone seemed to control the SE for at least 30-50 minutes because in these cases the second lidocaine bolus was administered at the same time or even before phenytoin due to the time taken to prepare the phenytoin infusion. Also, phenytoin concentration was not enough to control the seven episodes of SE that recurred at a mean of 102 minutes after the second bolus. Interestingly, this time coincides with the expected half life of this second bolus, which is usually in the range of 70-130 minutes.'3 6 Moreover, these seven episodes were treated with continuous infusion to which five of them responded. This confirms again the anticonvulsant actions of lidocaine in SE.
Therefore, the profile of lidocaine action in SE is similar to that of diazepam. From these data it seems clear that lidocaine is a rapid acting anticonvulsant and that doses of 3 mg/kg are usually necessary to control the SE until the antiepileptic actions of phenytoin or phenobarbital appear. In the eight cases in which continuous infusion was employed the SE was completely controlled in only three, perhaps because of the relatively low dose administered in comparison with the recommendations of others.81' Lidocaine may have proconvulsant effects but these symptoms are dose-dependent, usually appearing when more than 300 mg/hour have been infused, leading to plasma drug concentrations over 6 mg/1. '6 Thus, pending new experience, it seems reasonable not to exceed the maximum recommended dosage (200-300 mg/hour).7 Eleven episodes did not respond either to the boluses or to the continuous infusion. In our experience, as Browne suggested,7 episodes of SE that do not stop with 100 mg of lidocaine probably will not respond to subsequent doses of this drug. The absence of response to lidocaine is usually indicative of SE resistant to treatment and poor prognosis and is more commonly seen in patients with serious systemic disorders and in SE with partial onset.
In conclusion, lidocaine, like diazepam, is a rapid-acting anticonvulsant which is useful in short term management of the SE and may be indicated as a first line drug in patients in whom respiratory or consciousness depression is undesirable or as a second line drug in those episodes of SE that do not respond to diazepam. Our data suggest that, as in the treatment of ventricular arrythmias induced by myocardial infarction, prompt lidocaine administration for SE may be worthwhile particularly when patients are being transferred and management of respiratory depression is not possible.
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